Full Press Release Details
Pharmaceuticals Announces Successful Results of a Novel
Clinical Study of its Flagship Oral Insulin Capsule
Concept Study for a New Indication of Oral Insulin Capsule for Type
Israel - September 14, 2010 - Oramed Pharmaceuticals Inc. (OTCBB:
ORMP.OB) announced today successful results in an exploratory clinical trial
testing the effectiveness of its oral insulin capsule (ORMD-0801) in Type I
diabetes patients suffering from uncontrolled diabetes.
parallel to Oramed's main focus in developing an oral insulin capsule for
management of Type II diabetes the company is exploring an application of its
oral insulin capsule toward cases of uncontrolled Type I
diabetics. Unstable or labile diabetes is characterized by recurrent,
unpredictable and dramatic blood glucose swings often linked with irregular
hyperglycemia and sometimes serious hypoglycemia affecting Type I diabetes
patients. This newly completed exploratory study was a proof of
concept study for defining a novel indication for ORMD-0801. The encouraging
results justify further clinical development of ORMD-0801 capsule
application toward management of uncontrolled diabetes.
study marks an impressive milestone for Oramed" says Nadav Kidron, CEO of Oramed
Pharmaceuticals. "These results suggest a possible novel and unique indication
for our oral insulin product in the treatment of Type I diabetes in addition to
our main indication for Type II diabetes"
Oramed Pharmaceuticals
Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines presently delivered via injection. Oramed is seeking to
revolutionize the treatment of diabetes through its patented flagship product,
an orally ingestible insulin capsule currently in Phase 2 clinical trials.
Established in 2006, Oramed's technology is based on over 25 years of research
performed by top research scientists at Jerusalem's Hadassah Medical Center. The
Company's corporate and R&D headquarters are based in
information, please visit http://www.oramed.com.
the statements contained in this press release are forward-looking statements
which involve known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of the company, or
industry results, to be materially different from any future results,
performance or achievements expressed or implied by such forward looking
statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval for our product
candidates; competition from other pharmaceutical or biotechnology companies;
and the company's ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please refer to the
company's filings with the Securities and Exchange Commission for a
comprehensive list of risk factors that could cause actual results, performance
or achievements of the company to differ materially from those expressed or
implied in such forward looking statements. The company undertakes no obligation
to update or revise any forward-looking statements.
and Investor Relation Contacts:
Pharmaceuticals Inc.